It’s already been two years already since medical cannabis became legal in Germany. Back in January of 2017, the German parliament passed the “cannabis as medicine” act with unanimous approval, voting in favor of legalizing medical marijuana for German citizens who qualify for a medical prescription. The changes were set to take effect in March of that year.
Since then, however, the medical cannabis industry has been slow to set up shop, and in some cases, access for medical patients has been delayed due to supply shortages. High prices have also presented barriers to low-income patients with qualifying medical conditions.
Germany Sees A Change Of Pace
Fast forward to January of this year – Germany has been actively seeking producers in order to expand the current scope of its medical marijuana market and eliminate current reliance on product coming from the Netherlands and Canada. According to one Reuters interview, at least 79 growers submitted bids to the German Bundesinstitut für Arzneimittel und Medizinprodukte BfArM (Federal Institute for Drugs and Medical Devices) following the recent call for proposals.
The winner of the contract: Aurora Cannabis, a Canadian producer of medical cannabis whose mission is to “provide patients with reliable access to safe, consistent, and effective medical cannabis.”
The announcement came on Friday last week, when Aurora revealed that it had been awarded a contract to grow five of the thirteen lots of cannabis that the German government is planning to give out at this time. The contract will extend for the next four years and specify a minimum supply requirement of at least 4000 kg, or 4.4 US tons.
The maximum that any grower can be awarded is five lots in total. Two other companies were also selected; Aphria, another Canadian-based medical marijuana producer, also received the maximum possible five lots, while Demecan, a German company, received the remaining three lots.